Concentrating on biomarkers, HE4 has been reported to be superior to CA125 in separating benign, borderline ovarian tumors, cancers of the fallopian tubes, as well as early stage epithelial OC [29–39]. This evidence concerns the gene WFDC2 and fallopian tube cancer.